PDS Biotechnology Corporation (PDSB)
NASDAQ: PDSBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PDSB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $95.39M
- EPS (TTM)
- -$0.54
- Dividend yield
- None
- 52-week range
- 0.195 – 1.79
- Day range
- 0.7703 – 0.8451
- Volume / Avg
- 2.89M / 25.64M
- Beta
- —
- Shares outstanding
- 122.70M
52-week range
PDSB stock today
Shares of PDS Biotechnology (PDSB) finished lower on Nov 20 at $0.7774, a drop of 3.70% or $0.0299 per share, versus the S&P 500's 3.70% decline. Trading was light, with 2.89M shares changing hands, about 11% of the average daily volume. Shares are 56.6% below their 52-week high of $1.79, set on Oct 13, 2026 and 298.7% above the 52-week low of $0.195, in the middle of the past year's range.
PDSB is up 1.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 3.0%. PDS Biotechnology has posted a net loss over the last twelve months (EPS of -$0.54), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About PDS Biotechnology
Company profilePDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Frank K. Bedu-Addo Ph.D.
- Headquarters
- Princeton, NJ
- Employees
- 21
- IPO year
- 2015
- Website
- pdsbiotech.com
Financial highlights
Full financialsPDS Biotechnology reported a net loss of $34.5 million, compared with a loss of $37.6 million a year earlier. Diluted earnings per share came in at -$0.74.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-34.50M | $-37.61M | $-42.94M | $-40.85M | $-16.92M |
| EPS (diluted) | $-0.74 | $-1.03 | $-1.39 | $-1.43 | $-0.66 |
Analyst forecast
ForecastConsensus (2 analysts)
strong_buy
Avg. price target
$4.50+478.85%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.11 vs $-0.09
- Surprise
- -22.22%
PDSB news
All PDSB newsPDS Biotechnology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NRXPNRX Pharmaceuticals Inc. | 2.15 | -15.69% | $95.31M | vs PDSB |
| NBPNovaBridge Biosciences ADR | 0.83 | -5.66% | $96.28M | vs PDSB |
| DERMJourney Medical Corporation | 3.30 | -7.04% | $93.16M | vs PDSB |
| UNCYUnicycive Therapeutics Inc. | 3.35 | -5.10% | $97.77M | vs PDSB |
| CLLSCellectis S.A. ADR | 0.9209 | -7.89% | $92.76M | vs PDSB |
| CNTNCanton Strategic Holdings Inc. | 1.21 | -1.63% | $98.78M | vs PDSB |
| NERVMinerva Neurosciences Inc | 2.00 | -5.66% | $99.67M | vs PDSB |
| CATXPerspective Therapeutics Inc. | 0.7538 | -3.85% | $91.03M | vs PDSB |
Indexes, lists and sector
PDS Biotechnology stock FAQ
What is PDS Biotechnology's stock price today?
PDSB last traded at $0.7774 as of Nov 20, 4:00 PM EST, down 3.70% on the day. Prices are delayed at least 15 minutes.
Does PDS Biotechnology pay a dividend?
No. PDS Biotechnology does not currently pay a regular cash dividend.
Who is PDS Biotechnology's CEO?
Dr. Frank K. Bedu-Addo Ph.D. is the chief executive officer of PDS Biotechnology Corporation, which has about 21 employees.
Has PDSB ever split its stock?
Yes. The most recent PDSB stock split was a 1-for-20 split on Mar 18, 2019.
What is the PDSB 52-week high?
The 52-week high for PDSB is $1.79 and the 52-week low is $0.195. The stock is currently 56.6% below its high.